Does sweet turn sour? How aspartame aggravates atherosclerosis in a preclinical model

M. Yanina Pepino; Jaume Amengual

doi:10.1016/j.cmet.2025.04.003

Does sweet turn sour? How aspartame aggravates atherosclerosis in a preclinical model

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Aspartame, a low-calorie sweetener (LCS), was shown to be safe through extensive pre-clinical and clinical tests. However, epidemiological data link aspartame and other LCSs to higher cardiovascular risk. In this issue of Cell Metabolism, Wu et al.¹ show that aspartame accelerates atherosclerosis via a vagal-mediated insulin-dependent mechanism in a hyperlipidemic mouse model.

Original language	English (US)
Pages (from-to)	1043-1045
Number of pages	3
Journal	Cell Metabolism
Volume	37
Issue number	5
DOIs	https://doi.org/10.1016/j.cmet.2025.04.003
State	Published - May 6 2025

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Online availability

10.1016/j.cmet.2025.04.003

Library availability

Discover UIUC Full Text

Cite this

@article{b742cecd07a04153b718f624ae555233,

title = "Does sweet turn sour? How aspartame aggravates atherosclerosis in a preclinical model",

abstract = "Aspartame, a low-calorie sweetener (LCS), was shown to be safe through extensive pre-clinical and clinical tests. However, epidemiological data link aspartame and other LCSs to higher cardiovascular risk. In this issue of Cell Metabolism, Wu et al.1 show that aspartame accelerates atherosclerosis via a vagal-mediated insulin-dependent mechanism in a hyperlipidemic mouse model.",

author = "Pepino, {M. Yanina} and Jaume Amengual",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

month = may,

day = "6",

doi = "10.1016/j.cmet.2025.04.003",

language = "English (US)",

volume = "37",

pages = "1043--1045",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Does sweet turn sour? How aspartame aggravates atherosclerosis in a preclinical model

AU - Pepino, M. Yanina

AU - Amengual, Jaume

PY - 2025/5/6

Y1 - 2025/5/6

N2 - Aspartame, a low-calorie sweetener (LCS), was shown to be safe through extensive pre-clinical and clinical tests. However, epidemiological data link aspartame and other LCSs to higher cardiovascular risk. In this issue of Cell Metabolism, Wu et al.1 show that aspartame accelerates atherosclerosis via a vagal-mediated insulin-dependent mechanism in a hyperlipidemic mouse model.

AB - Aspartame, a low-calorie sweetener (LCS), was shown to be safe through extensive pre-clinical and clinical tests. However, epidemiological data link aspartame and other LCSs to higher cardiovascular risk. In this issue of Cell Metabolism, Wu et al.1 show that aspartame accelerates atherosclerosis via a vagal-mediated insulin-dependent mechanism in a hyperlipidemic mouse model.

UR - http://www.scopus.com/inward/record.url?scp=105003742829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=105003742829&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2025.04.003

DO - 10.1016/j.cmet.2025.04.003

M3 - Comment/debate

C2 - 40334641

AN - SCOPUS:105003742829

SN - 1550-4131

VL - 37

SP - 1043

EP - 1045

JO - Cell Metabolism

JF - Cell Metabolism

IS - 5

ER -

Does sweet turn sour? How aspartame aggravates atherosclerosis in a preclinical model

Abstract

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this